Your browser doesn't support javascript.
loading
How can we deliver on the promise of precision medicine in oncology and beyond? A practical roadmap for action.
Baird, Anne-Marie; Westphalen, C Benedikt; Blum, Sandra; Nafria, Begonya; Knott, Tanya; Sargeant, Ify; Harnik, Helena; Brooke, Nicholas; Wicki, Nicole; Wong-Rieger, Durhane.
Afiliação
  • Baird AM; Lung Cancer Europe (LuCE) Bern Switzerland.
  • Westphalen CB; From Testing to Targeted Treatments (FT3) Program Team, The Synergist Brussels Belgium.
  • Blum S; Comprehensive Cancer Center Munich and Department of Medicine III University Hospital, LMU Munich Munich Germany.
  • Nafria B; From Testing to Targeted Treatments (FT3) Program Team, The Synergist Brussels Belgium.
  • Knott T; Roche Basel Switzerland.
  • Sargeant I; From Testing to Targeted Treatments (FT3) Program Team, The Synergist Brussels Belgium.
  • Harnik H; Institut de Recerca Sant Joan de Déu Barcelona Spain.
  • Brooke N; Innovation and Research Department, Hospital Sant Joan de Déu Pg Barcelona Spain.
  • Wicki N; From Testing to Targeted Treatments (FT3) Program Team, The Synergist Brussels Belgium.
  • Wong-Rieger D; Sarah Jennifer Knott (SJK) Foundation Dublin Republic of Ireland.
Health Sci Rep ; 6(6): e1349, 2023 Jun.
Article em En | MEDLINE | ID: mdl-37359405
ABSTRACT

Background:

Precision medicine (PM) is a form of personalized medicine that recognizes that individuals with the same condition may have different underlying factors and uses molecular information to provide tailored treatments. This approach can improve treatment outcomes and transform lives through favorable risk/benefit ratios, avoidance of ineffective interventions, and possible cost savings, as evidenced in the field of lung cancer and other oncology/therapeutic settings, including cardiac disease, diabetes, and rare diseases. However, the potential benefits of PM have yet to be fully realized.

Discussion:

There are many barriers to the implementation of PM in clinical practice, including fragmentation of the PM landscape, siloed approaches to address shared challenges, unwarranted variation in availability and access to PM, lack of standardization, and limited understanding of patients' experience and needs throughout the PM pathway. We believe that a diverse, intersectoral multistakeholder collaboration, with three main pillars of activity generation of data to demonstrate the benefit of PM, education to support informed decision-making, and addressing barriers across the patient pathway, is necessary to reach the shared goal of making PM an accessible and sustainable reality. Besides healthcare providers, researchers, policymakers/regulators/payers, and industry representatives, patients in particular must be equal partners and should be central to the PM approach-from early research through to clinical trials and approval of new treatments-to ensure it represents their entire experience and identifies barriers, solutions, and opportunities at the point of delivery.

Conclusion:

We propose a practical and iterative roadmap to advance PM and call for all stakeholders across the healthcare system to employ a collaborative, cocreated, patient-centered methodology to close gaps and fully realize the potential of PM.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article